Mounjaro vs Ozempic: Which Is Better for Weight Loss?
Mounjaro vs Ozempic compared: how tirzepatide and semaglutide work, trial weight loss results, side effects, cost, and who tends to get prescribed each.
If you’re comparing Mounjaro vs Ozempic, you’re really asking a bigger question: which GLP-1 is best for weight loss, and which one will you actually be able to stay on? The honest answer is that the research favors one on average, but the “better” medication is the one that fits your health, your budget, and your tolerance for side effects.
This article is educational and not medical advice. Your prescriber should make the final call on any medication.
The Short Answer
On average, Mounjaro (tirzepatide) produces more weight loss than Ozempic (semaglutide). In the head-to-head SURMOUNT-5 trial of adults with obesity but without diabetes, tirzepatide led to an average 20.2% weight loss at 72 weeks, versus 13.7% with semaglutide. Averages hide a lot of variation, though, and a medication you can’t tolerate or afford won’t help anyone.
One caveat on names: Mounjaro and Ozempic are the brand names approved for type 2 diabetes. The same active ingredients are sold for weight management as Zepbound (tirzepatide) and Wegovy (semaglutide). The comparison below applies to the drugs, whichever brand your prescriber uses. For the Wegovy side of the story, see our Wegovy vs Ozempic breakdown.
How They Work: Dual Agonist vs GLP-1 Only
Ozempic (semaglutide) mimics one gut hormone, GLP-1. It slows stomach emptying, signals fullness to the brain, and reduces appetite.
Mounjaro (tirzepatide) mimics two hormones: GLP-1 and GIP. This is why it’s called a dual agonist. GIP appears to add to the appetite and metabolic effects of GLP-1, which is the leading explanation for the larger average results.
Both are once-weekly injections that you start at a low dose and increase gradually.
Weight Loss Results From Clinical Trials
- SURMOUNT-5 (obesity, no diabetes, head-to-head): about 20.2% average weight loss on tirzepatide vs 13.7% on semaglutide at 72 weeks.
- SURPASS-2 (type 2 diabetes, head-to-head): tirzepatide led to greater weight loss and larger A1C reductions than semaglutide 1 mg.
Keep in mind that trial participants also received lifestyle support. Real-world results vary with dose, adherence, protein intake, activity, and how long you stay on treatment. If your progress stalls on either drug, our guide to the GLP-1 plateau explains what to do.
Mounjaro vs Ozempic at a Glance
| Mounjaro (tirzepatide) | Ozempic (semaglutide) | |
|---|---|---|
| Mechanism | GIP + GLP-1 dual agonist | GLP-1 only |
| Dosing | Once weekly injection | Once weekly injection |
| FDA-approved for | Type 2 diabetes (Zepbound for weight management) | Type 2 diabetes (Wegovy for weight management) |
| Average weight loss in head-to-head trials | Greater | Lower |
| Common side effects | Nausea, diarrhea, constipation, vomiting | Nausea, diarrhea, constipation, vomiting |
| Cardiovascular outcome evidence | Growing | Stronger, longer track record |
| Typical starting point | Often for larger weight-loss goals | Often the first GLP-1 prescribed |
Side Effect Profiles
The side effects are strikingly similar because both drugs act on GLP-1 pathways. Expect nausea, constipation, diarrhea, reflux, and fatigue, mostly in the first weeks and after each dose increase. Neither drug is clearly “gentler” for everyone; individual response matters more than the label.
Constipation deserves special attention because it’s one of the most common reasons people struggle on treatment. If that’s you, start with our guides on Ozempic constipation and tirzepatide constipation relief. For early-weeks expectations, see Mounjaro side effects in weeks 1–4.
Both carry boxed warnings about thyroid C-cell tumors seen in rodents, and neither is suitable for people with a personal or family history of medullary thyroid cancer or MEN 2. Discuss pancreatitis, gallbladder, and kidney history with your prescriber.
Cost and Insurance
Both are expensive without coverage, and coverage varies widely by plan. Insurers often cover the diabetes-labeled versions (Mounjaro, Ozempic) for type 2 diabetes but may exclude weight-loss use. Manufacturer savings programs, formulary changes, and cash-pay pricing shift often, so confirm current numbers with your pharmacy and insurer. Our GLP-1 cost breakdown covers the typical ranges.
Who Tends to Be Prescribed Each
Prescribers commonly consider:
- Ozempic/semaglutide for patients with type 2 diabetes, those with established cardiovascular disease (given its outcome data), or when insurance favors it.
- Mounjaro/tirzepatide for patients who need larger weight reduction, or who didn’t reach their goals on semaglutide.
- Tolerability and access: supply, coverage, and how you responded to earlier doses often decide it in practice.
Switching is common, and it’s a conversation for your prescriber, not a DIY change.
So, Which Is Better for You?
If the question is purely average weight loss, tirzepatide has the edge in head-to-head trials. If the question is which you’ll tolerate, afford, and stay on, the answer is personal. And staying on treatment matters: many people stop because side effects pile up, not because the drug failed.
Make Either Medication Easier to Stay On
Whichever you choose, the day-to-day side effects are where most people struggle. The FlowWell GLP-1 Comfort Guide gives you practical, evidence-based strategies for nausea, constipation, and appetite changes, and the Starter Bundle (3 guides) adds deeper help on fiber, protein, and adherence. Browse the FlowWell guides and make your next dose a little easier.